Complementary Therapies

  • Jost LanghorstEmail author


“Complementary and alternative medicine (CAM) is used to described a wide variety of methods, procedures, substances, and medical systems. Complementary medicine is practiced in addition to conventional medicine, whereas alternative medicine is intended to replace standard methods. For this reason, alternative methods are generally rejected by the scientific community.”


  1. Langhorst J (2006) Gastrointestinale Erkrankungen: Chronisch entzündliche Darmerkrankungen. In: Dobos G, Deuse U, Michalsen A (eds) Chronische Erkrankungen integrativ. Elsevier, Urban & Fischer, AmsterdamGoogle Scholar
  2. Langhorst J, Anthonisen IB, Steder-Neukamm U, Lüdtke R, Spahn G, Michalsen A, Dobos GJ (2005) Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in German patients with inflammatory bowel disease: results from a national survey. Inflamm Bowel Dis 11(3):287–295CrossRefGoogle Scholar

Suggested Readings

  1. Langhorst J, Wulfert H, Lauche R, Klose P, Cramer H, Dobos GJ, Korzenik J (2014) Systematic review on complementary and alternative medicine treatments in inflammatory bowel diseases. J Crohn’s Colitis 9(1):86–106CrossRefGoogle Scholar
  2. Wieland LS, Manheimer E, Berman BM (2011) Development and classification of an operational definition of complementary and alternative medicine for the Cochrane collaboration. Altern Ther Health Med 17(2):50–59PubMedPubMedCentralGoogle Scholar
  3. Langhorst J, Anthonisen I, Steder-Neukamm U, Lüdtke R, Spahn G, Michalsen A, Dobos GJ (2007) Patterns of complementary and alternative medicine (CAM) use in patients with inflammatory bowel disease: perceived stress is a potential indicator for CAM use. Complement Ther Med 15(1):30–37CrossRefGoogle Scholar
  4. Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL et al (1999) Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 94:427–433CrossRefGoogle Scholar
  5. Gupta I, Parihar A, Malhotra P et al (2001) Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 67:391–395CrossRefGoogle Scholar
  6. Gupta I, Parihar A, Malhotra P et al (1997) Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 2:37–43PubMedGoogle Scholar
  7. Gerhardt H, Seifert F, Buvari P et al (2001) Therapy of active Crohn disease with Boswellia serrata extract H15. Z Gastroenterol 39:11–17CrossRefGoogle Scholar
  8. Holtmeier W, Zeuzem S, Preiss J et al (2011) Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn’s disease: good safety profile but lack of efficacy. Inflamm Bowel Dis 17(2):573–582CrossRefGoogle Scholar
  9. Langhorst J, Varnhagen I, Schneider SB, Albrecht U, Rueffer A, Stange R, Michalsen A, Dobos GJ (2013a) Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared to mesalazine in maintaining remission in ulcerative colitis – a double-blind, double dummy study. Aliment Pharmacol Ther 38(5):490–500CrossRefGoogle Scholar
  10. Biedermann L, Mwinyi J, Scharl M et al (2013) Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis - an open pilot study. J Crohns Colitis 7(4):271–279CrossRefGoogle Scholar
  11. Huber R, Ditfurth AV, Amann F et al (2007) Tormentil for active ulcerative colitis: an open-label, dose-escalating study. J Clin Gastroenterol 41:834–838CrossRefGoogle Scholar
  12. Hanai H, Iida T, Takeuchi K et al (2006) Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4:1502–1506CrossRefGoogle Scholar
  13. Lang A, Salomon N, Wu JCY et al (2015) Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol 13:1444–1449CrossRefGoogle Scholar
  14. Omer B, Krebs S, Omer H, Noor TO (2007) Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study. Phytomedicine 14(2–3):87–95CrossRefGoogle Scholar
  15. Krebs S, Omer TN, Omer B (2010) Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn’s disease - a controlled clinical trial. Phytomedicine 17(5):305–309CrossRefGoogle Scholar
  16. Langmead L, Feakins RM, Goldthorpe S et al (2004) Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther 19:739–747CrossRefGoogle Scholar
  17. Ben-Arye E, Goldin E, Wengrower D et al (2002) Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol 37:444–449CrossRefGoogle Scholar
  18. Tang T, Targan SR, Li ZS, Xu C, Byers VS, Sandborn WJ (2011) Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther 33(2):194–202CrossRefGoogle Scholar
  19. Sandborn WJ, Targan SR, Byers VS, Rutty DA, Mu H, Zhang X, Tang T (2013) Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol 108:90–98CrossRefGoogle Scholar
  20. Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM (2011) Treatment of Crohn’s disease with cannabis: an observational study. Isr Med Assoc J 13(8):455–458PubMedGoogle Scholar
  21. Naftali T, Bar-Lev Schleider L, Dotan I et al (2013) Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol 11(10):1276–1280CrossRefGoogle Scholar
  22. Joos S, Brinkhaus B, Maluche C et al (2004) Acupuncture and moxibustion in the treatment of active Crohn’s disease: a randomized controlled study. Digestion 69:131–139CrossRefGoogle Scholar
  23. Joos S, Wildau N, Kohnen R et al (2006) Acupuncture and moxibustion in the treatment of ulcerative colitis: a randomized controlled study. Scand J Gastroenterol 41:1056–1063CrossRefGoogle Scholar
  24. Ji J, Lu Y, Liu H et al (2013) Acupuncture and moxibustion for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med 2013:158352CrossRefGoogle Scholar
  25. Lee DH, Kim JI, Lee MS et al (2010) Moxibustion for ulcerative colitis: a systematic review and meta-analysis. BMC Gastroenterol 10:36CrossRefGoogle Scholar
  26. Elsenbruch S, Langhorst J, Popkirowa K et al (2005) Effects of mind-body therapy on quality of life and neuroendocrine and cellular immune functions in patients with ulcerative colitis. Psychother Psychosom 74:277–287CrossRefGoogle Scholar
  27. Jedel S, Hoffman A, Merriman P et al (2014) A randomized controlled trial of mindfulness-based stress reduction to prevent flare-up in patients with inactive ulcerative colitis. Digestion 89:142–155CrossRefGoogle Scholar
  28. Berrill JW, Sadlier M, Hood K et al (2014) Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. J Crohns Colitis 8(9):945–955CrossRefGoogle Scholar
  29. Levenstein S, Prantera C, Varvo V, Scribano ML, Berto E, Andreoli A, Luzi C (1994) Psychological stress and disease activity in ulcerative colitis: a multidimensional cross-sectional study. Am J Gastroenterol 89(8):1219–1225PubMedGoogle Scholar
  30. Levenstein S, Prantera C, Varvo V et al (2000) Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol 95:1213–1220CrossRefGoogle Scholar
  31. Langhorst J, Hofstetter A, Wolfe F et al (2013b) Short-term stress, but not mucosal healing nor depression was predictive for the risk of relapse in patients with ulcerative colitis: a prospective 12-month follow-up study. Inflamm Bowel Dis 19:2380–2386CrossRefGoogle Scholar
  32. Mizrahi MC, Reicher-Atir R, Levy S, Haramati S, Wengrower D, Israeli E, Goldin E (2012) Effects of guided imagery with relaxation training on anxiety and quality of life among patients with inflammatory bowel disease. Psychol Health 27:1463–1479CrossRefGoogle Scholar
  33. Keefer L, Taft TH, Kiebles JL, Martinovich Z, Barrett TA, Palsson OS (2013) Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis. Aliment Pharmacol Ther 38:761–771CrossRefGoogle Scholar
  34. Sonnenberg A (1990) Occupational mortality of inflammatory bowel diseases. Digestion 46(1):10–18CrossRefGoogle Scholar
  35. Khalili H, Ananthakrishnan AN, Konijeti GG et al (2013) Physical activity and risk of inflammatory bowel disease: prospective study from the Nurses’ Health Study cohorts. BMJ 347:f6633. CrossRefPubMedPubMedCentralGoogle Scholar
  36. Nunes T, Etchevers MJ, Domènech E, Tobacco-Eneida Study Group of GETECCU et al (2013) Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era. Aliment Pharmacol Ther 38(7):752–760CrossRefGoogle Scholar
  37. Cramer H, Schafer M, Schols M et al (2017) Randomised clinical trial: yoga vs written self-care advice for ulcerative colitis. Aliment Pharmacol Ther 45(11):1379–1389CrossRefGoogle Scholar
  38. Schneider A, Streitberger K, Joos S (2007) Acupuncture treatment in gastrointestinal diseases: a systematic review. World J Gastroenterol 13(25):3417–3424CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Internal and Integrative MedicineKlinikum Bamberg, Sozialstiftung BambergBambergGermany

Personalised recommendations